Press releases
- Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
- Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
- Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
- Neurocrine Biosciences Reports First Quarter 2024 Financial Results
- Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
- Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
- Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
More ▼
Key statistics
As of last trade Neurocrine Biosciences Inc (0K6R:LSE) traded at 141.49, -4.62% below its 52-week high of 148.34, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 142.26 |
Average volume | 341.44 |
---|---|
Shares outstanding | 100.64m |
Free float | 99.36m |
P/E (TTM) | 38.94 |
Market cap | 14.26bn USD |
EPS (TTM) | 3.64 USD |
Data delayed at least 20 minutes, as of May 07 2024 15:03 BST.
More ▼